afamelanotide [621]



afamelanotide


SMILES CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)C(C)C
InChIKey UAHFGYDRQSXQEB-LEBBXHLNSA-N
Sequence SYSXEHFRWGKPV
HELM PEPTIDE1{[ac].S.Y.S.[Nle].E.H.[dF].R.W.G.K.P.V.[am]}$$$$

Chemical Properties

Hydrogen bond acceptors 21
Hydrogen bond donors 23
Rotatable bonds 50
Log P -4.100
Molecular weight (Da) 1645.8
Stereochemistry info unspecified


Bioactivities

Receptor Activity Source
Protein Gene Species Family Class Type Min Avg Max Database
Receptor Activity Source
Protein Gene Species Family Class Type Min Avg Max Database

afamelanotide


Drug properties

Molecular type Peptide
Physiological/Surrogate Surrogate
Approved drug Yes

Distribution across phases (no. indications)

Phase I 0
Phase II 5
Phase III 0
Phase IV 1


Sankey plot


Drug Information

Target Disease
Gene Protein Receptor family Ligand type Class Name Phase ICD11 ATC Association score